Revive Rx LLC dba Revive Rx Pharmacy
Has Revive Rx LLC dba Revive Rx Pharmacy received an FDA warning letter about GLP-1 drugs?
No FDA warning letter to Revive Rx LLC dba Revive Rx Pharmacy naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 2 drug recall reports for it naming tirzepatide, the latest initiated Apr 20, 2024.
FDA records in this index name Revive Rx LLC dba Revive Rx Pharmacy from May 11, 2023 to Apr 20, 2024.
- Type named in FDA records
- Not stated
- FDA warning letters
- 0
- Drug recall reports
- 2
- Drugs named
- Tirzepatide
- Latest record
- Apr 20, 2024
FDA warning letters
No FDA warning letters in this index.
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Apr 20, 2024 | Tirzepatide 10 mg/0.5 mL Sterile Solution, 2 mL Multi-dose vial, Rx only, This is a Compounded Product By: Revive RX Pharmacy, 3831 Golf Dr A, Houston, TX 77... | Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionate | Class I | Ongoing | D-0511-2024 |
| May 11, 2023 | Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial, Rx Only, For Sub-Q Use Only, Compounded Drug Product By: Revive Rx, 3831 Golf Dr A, Houston, TX 77018, N... | Sub-potent Drug | Class II | Ongoing | D-0771-2023 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Revive RX LLC, dba Revive RX Pharmacy, Houston, TX (503A)
7 listed actions, including 4 Form 483s, 1 warning letter and 1 untitled letter (2021 to 2026).
| Document | |||
|---|---|---|---|
| Mar 27, 2026 | Form 483 | 483 Issued 3/27/2026 | fda.gov |
| Sep 22, 2025 | Warning letter | Warning Letter Issued 09/22/2025 | fda.gov |
| Feb 7, 2025 | Form 483 | 483 Issued 02/07/2025 | fda.gov |
| Jan 22, 2025 | FMD-145 letter | FMD-145 Letter Issued 01/22/2025 | Not linked by FDA |
| Jun 30, 2023 | Untitled letter | Untitled Letter Issued 06/30/2023 | FDA copy (archived) |
| May 4, 2022 | Form 483 | 483 Issued 05/04/2022 | FDA copy (archived) |
| Aug 6, 2021 | Form 483 | 483 Issued 08/06/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Revive RX Pharmacy (Revive RX LLC), Houston, TX.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- openFDA drug recall enforcement reports
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.